ReviewNew microbes and new infections2026
The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches.
Review in New microbes and new infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human T-cell leukaemia virus type 1 (HTLV-1) is an oncogenic retrovirus responsible for severe diseases, including adult T-cell leukaemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Despite its significant global prevalence, specific direct-acting antiviral therapies remain unavailable. This review comprehensively surveys the HTLV-1 protease (HTLV-1 PR), a pivotal homodimeric aspartic protease essential for viral maturation and infectivity, as a critical antiviral drug target. A detailed analysis of HTLV-1 PR's narrow substrate specificity, influenced by specific subsite interactions, highlights its distinction from the human immunodeficiency virus-1 protease (HIV-1 PR) and explains the limited efficacy of cross-targeting existing HIV-1 inhibitors. The review critically assesses current inhibitor development strategies, including the challenges posed by its unique structural architecture and the need for novel, HTLV-1-specific chemical scaffolds. We discuss the promise of structure-based drug design,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.